Opinion|Videos|September 28, 2026
Choosing Between Regimens, Future Directions, and Key Takeaways
In the closing discussion, the faculty address how they choose between the available chemoimmunotherapy regimens and where the field is heading.
Advertisement
Episodes in this series
In the closing discussion, the faculty address how they choose between the available chemoimmunotherapy regimens and where the field is heading. The segment closes with the key takeaways, including reviewing the takeaways from the TOPAZ-1 study data, the consistency of independent real-world datasets, and the survival signal reported in meta-analysis.
Advertisement
Related to this article
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
C. Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible framework in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
Advertisement
Advertisement
Trending on CancerNetwork
1
Acting on a HER2 Result and Navigating Access to Therapy
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
4
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
5